Improving economic conditions and a more favorable regulatory environment give Goldman Sachs catalysts to benefit from in the ...

Goldman Sachs analyst Salveen Richter initiated coverage of Summit Therapeutics (SMMT) with a Buy rating and $42 price target a Summit’s lead ...

ASX 200 futures are down 69pts (-0.84%) as of 8:30 am AEDT. In a nutshell: Nasdaq logs worst day in a month S&P 500 turns ...

Emasan AG is offering around 26.5M shares in Swiss Novartis (NVS) through Goldman Sachs, potentially raising $3B, Pablo Mayo Cerqueiro of ...

Hedge funds are making some adjustments to their tech-investing playbook.